Trials / Withdrawn
WithdrawnNCT00704392
Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL647 and XL147 Administered in Combination Daily to Subjects With Solid Tumors
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Exelixis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety, tolerability, and highest safe doses of XL647 in combination with XL147 in adults with solid tumors. XL647 is a small molecule that potently inhibits multiple receptor kinases, including EGFR, VEGFR2 (KDR), and ErbB2. XL147 is a new chemical entity that inhibits PI3 Kinase. Inactivation of PI3K has been shown to inhibit growth and induce apoptosis (programmed cell death) in tumor cells.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XL647 | Tablets supplied at 50-mg strength administered orally daily |
| DRUG | XL147 | Gelatin capsules supplied at 25-mg and 100-mg strengths administered orally daily |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2009-12-01
- Completion
- 2009-12-01
- First posted
- 2008-06-24
- Last updated
- 2015-08-20
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00704392. Inclusion in this directory is not an endorsement.